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Summary and general discussion 
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Summary 
The overall aim of this thesis was to provide more insight into the neurobiological 
mechanisms underlying comorbid cognitive symptoms in psychosis and continued 
frequent substance use. In the first part of this thesis, neurobiological mechanisms 
of cognitive symptoms in subjects with a psychotic disorder were examined 
(chapter 2 – chapter 4), with a focus on the cholinergic system. In the second part 
of this thesis, underlying neurobiological mechanisms of substance use were 
examined, focusing on mechanisms underlying continued frequent cannabis use 
(chapter 5 – chapter 7). In this final chapter, the main findings of these studies are 
summarized and discussed as well as the clinical implications of these findings and 
future directions.  
In chapter 2, the effectiveness of pharmacological interventions for separate 
cognitive domains critically impaired in schizophrenia patients, as established by 
the MATRICS initiative, were reviewed. The reviewed studies provided evidence 
for a role of the dopaminergic D1 receptor subtype in processing speed and 
reasoning and problem solving. The serotonergic, GABA-ergic and glutamatergic 
system were found to be involved in different aspects of memory. The latter 
system was also found to be involved in reasoning and problem solving. Finally, 
nicotine acetylcholine receptors (nAChRs) have been found to modulate attention 
and vigilance. However, results from a limited number of studies suggested that 
memory functions may be enhanced with agents targeting the muscarinic system. 
Overall, these findings indicate that different mechanisms underlie separate 
aspects of cognition which suggest that patients with schizophrenia with different 
cognitive profiles may benefit from different intervention strategies.  
In chapter 3, the role of the muscarinic M1 receptor in cognitive function in 
subjects with a psychotic disorder was examined by means of the M1 antagonist 
biperiden as a pharmacological challenge. Blocking the M1 receptor significantly 
impaired both visual and verbal learning and memory which is indicative of a role 
of this receptor in these cognitive domains. An interaction effect was found 
between medication and group on reasoning and problem solving; in the psychosis 
group this domain improved after biperiden administration, whereas performance 
on this domain in the healthy control group worsened after biperiden 
administration. This indicates that the effect of M1 antagonism on this domain was 
different for both groups. The effects of biperiden on the other cognitive domains 
were comparable in the psychosis and the healthy control group. Although these 
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results confirm a role of the M1 receptor subtype in memory performance, the lack 
of a differential effect of M1 blockade between the studied groups could indicate 
that M1 receptor deficits were not present in our sample and are possibly only 
present in older, chronic schizophrenia patients. 
 
Chapter 4 elucidates on the role of the cholinergic system in psychosis and 
associated cognitive impairments. We examined whether brain choline (cho) 
concentrations in the anterior cingulate cortex (ACC) and striatum differed 
between subjects with a psychotic disorder and controls and whether blockade of 
the M1 receptor influenced cho concentrations in these regions. In addition, it was 
examined if cho concentrations were associated with separate domains of 
cognition. The significant inverse correlation between attention and striatal cho 
found in the psychotic subjects confirms previous findings of a role of the 
cholinergic system in cognitive symptoms of psychosis. Although we cannot rule 
out that there are cholinergic abnormalities present in chronic schizophrenia 
patients, the lack of a significant difference in cho concentrations between the 
groups, both after biperiden and placebo, in both brain regions could indicate that 
no severe cholinergic abnormalities were present in this sample of relative young 
and well-functioning psychotic subjects.  
 
In chapter 5, the relationship between working memory network function and 
continued, frequent cannabis use was examined in a longitudinal 3-year follow-up 
functional MRI study. In the baseline study, it was found that despite comparable 
working memory network functioning and performance on a working-memory task 
(behavioral) in heavy cannabis users and healthy non-using control subjects, a 
stronger working memory network response was related to increased weekly 
cannabis use over a 6-month period. The follow-up results showed that despite 
improved performance on the working memory task in both groups, working 
memory network function did not change over the 3-year period. Contrary to 
previous findings, no association was found between baseline working memory 
network response and cannabis, nicotine, alcohol or other recreational drug use. 
These results suggest that continued cannabis use does not significantly influence 
working memory network functioning. 
 
Elaborating on previously findings of increased activation in response to cannabis 
cues in heavy cannabis users compared to controls in the ventral tegmental area 
(VTA), as well as a higher activation in the ACC, orbitofrontal cortex (OFC) and 
striatum in more problematic cannabis users compared to less problematic 
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cannabis users, chapter 6 describes the results of a follow-up study investigating 
the value of neural cue-reactivity in these brain regions in predicting changes in 
weekly cannabis use and related problem severity over a 3-year period. None of 
the regions identified in the baseline study were found to predict weekly cannabis 
use at 3-year follow-up. However, increased activation in the left (dorsal) striatum 
predicted cannabis related problem severity after 3 years which suggest cue-
reactivity might be a useful tool in predicting transition to problematic cannabis 
use and possibly cannabis dependence.  
In chapter 7, the prevalence of substance use and substance use disorders in 
22q11.2 deletion syndrome (22q11DS), a population at high risk for developing 
psychotic disorders, was determined. The deletion on chromosome 22q11.2 
defining this group of patients includes genes which have been associated with 
both psychotic disorders and substance use disorders. Therefore, investigating 
patterns of substance use in these patients may provide valuable insight in the 
genetic aspects of both psychosis and substance use disorders. Compared to 
psychotic patients (88%) and healthy controls subjects (82%), the prevalence of 
overall substance use (37%) and substance use disorders (1.2%) was low in 
22q11DS patients. Furthermore, we found that these patients were at decreased 
risk for overall substance use as well alcohol and nicotine use separately. 
Interestingly, prevalence of recreational drug use did not differ between the three 
groups. In addition, within the 22q11DS group no relationship was found between 
prevalence of substance disorders and psychosis, COMT-genotype and intelligence 
quotient (IQ). Comparable to findings in the general population, substance use was 
more common in male than in female 22q11DS patients. Further research into 
both neurobiological and environmental factors contributing to this decreased risk 
of substance use and substance use disorders in 22q11DS could provide new 
insights in the genetic aspects of substance use disorders in both psychotic 
patients as well as the general population.  
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General discussion  
The overall aim of this dissertation was to further examine neurobiological 
mechanisms underlying cognitive functioning in subjects with a psychotic disorder 
and substance use, heavy cannabis use in particular. In the first part of this 
dissertation, previous conducted studies investigating the effects of several 
pharmacological treatment strategies on cognitive symptoms in psychosis were 
reviewed. Furthermore, the role of the cholinergic system in these symptoms was 
examined. In the second part, possible neurobiological mechanisms of continued, 
frequent cannabis use were investigated using a longitudinal design. Moreover, 
prevalence and patterns of overall substance use and substance use disorders in 
22q11.2 deletion syndrome (22q11DS) were examined in order to provide insight 
in genetic aspects contributing to substance use disorders.  
 
Neurobiological mechanisms underlying cognitive symptoms of psychosis 
Identifying potential targets for cognitive enhancement in schizophrenia: 
evidence from previous studies 
The urgent need for effective treatment strategies for cognitive impairments 
reported by patients with a psychotic disorder has led to a tremendous increase of 
studies attempting to identify molecular targets which can enhance cognition in 
these patients. In chapter 2, several of these studies were reviewed. Both studies 
examining the effects of existing antipsychotics, which mainly target the 
dopaminergic D2 and serotonin 2A (5-HT2A) receptors, as well as studies examining 
pharmacological interventions targeting other systems were taken into account. 
An important observation is that the studies reviewed in this chapter do not 
provide evidence for positive effects of neither atypical and typical antipsychotics 
on cognitive impairments in schizophrenia, despite previous suggestions that 
atypical antipsychotics are superior to first-generation antipsychotics in treatment 
of cognitive symptoms (1). Although overall results have been unsatisfactory, some 
potential molecular targets have been identified over the years. Among the targets 
that hold promise for enhancement of cognitive function in psychosis are the 
dopamine D1 receptors, serotonin 5-HT1A and 5-HT3A receptors, nicotinic α7 
receptors, GABAA receptors and NMDA receptors. It appears that dysfunction in 
separate cognitive domains are related to different neurobiological processes 
which could partly explain unsatisfactory results as the majority of the studies 
combine separate cognitive domains in one overall cognitive composite score.  
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Neurobiological mechanisms underlying cognitive impairment in psychosis: 
role of the cholinergic system  
Although the cholinergic system has been repeatedly linked to a variety of 
cognitive domains (2), relatively little in-vivo research has been conducted on the 
role of cholinergic neurotransmission in psychotic disorders (3). Nonetheless, 
abnormalities in both nicotine acetylcholine receptors (nAChRs) and muscarinic 
acetylcholine receptors (mAChRs) have been described in post-mortem brains of 
patients with schizophrenia (4–10). However, due to the design of these post-
mortem studies, it is currently unknown how these cholinergic abnormalities 
relate to cognitive impairments in these patients. Therefore, the aim of chapters 3 
and 4 was to provide more insight in this relationship in-vivo. We focused on the 
muscarinic M1 receptor subtype because this subtype has been linked to both 
psychosis and cognition and because of all the mAChR subtypes, it has the highest 
expression rates in the central nervous system (CNS), particularly in brain regions 
instrumental for cognitive function including the striatum, frontal cortex and the 
hippocampus. We differentiated between 7 cognitive domains which have been 
found to be critically impaired in schizophrenia as established by the Measurement 
and Treatment to Improve Cognition in Schizophrenia (MATRICS) initiative since 
our findings in chapter 2 indicated that separate domains of cognition are 
associated with different neurobiological mechanisms. Cognitive functioning was 
measured with the Cambridge Neuropsychological Automated Test Battery 
(CANTAB) schizophrenia test battery which covers all the MATRICS domains and is 
considered to be the ‘golden standard’. In line with previous studies in both 
animals and humans, the findings described in chapter 3 provide evidence for a 
role of the M1 receptor in (verbal and visual) memory. Contrary to previous 
findings, acute M1 receptor blockade did not affect working memory in both 
psychotic subjects and healthy controls, which could be related to characteristics 
of the  task we used. Moreover, the lack of a differential effect between the two 
groups suggests that, contrary to post-mortem findings in schizophrenia (6,7,11), 
M1 deficits were not present in our sample. However, it must be noted that M1 
receptor density has been found to decrease with increasing age in healthy 
subjects (12) and that our participants were younger than the patients included in 
previous post-mortem studies. Nevertheless, these findings are in line with the 
lack of difference in choline concentrations in the ACC and striatum between 
medication-free subjects with a psychotic disorder and healthy controls (after 
placebo) described in chapter 4. These latter findings are in contrast with previous 
studies reporting increased choline concentrations in both first-episode and 
chronic and medicated and un-medicated psychotic patients in different brain 
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regions (13–15). Compared to these studies however, our sample was smaller and 
we included subjects with a diagnosis within the psychosis spectrum instead of 
limiting the inclusion criteria to schizophrenia. This, in addition to the positive 
relationship found between choline concentrations and duration of untreated 
psychosis (16), could suggest that cholinergic abnormalities are only present in 
older patients with (chronic) schizophrenia or in a subgroup of patients with severe 
cognitive impairments as proposed by Scarr and colleagues (11). The psychotic 
subjects we included displayed less severe cognitive impairments compared to 
schizophrenia patients generally included (17). Although this hypothesis has not 
been investigated, our finding of an inverse correlation between striatal choline 
levels and attention in psychotic subjects but not in controls (chapter 4), would be 
in line with this hypothesis since attention was one of the few cognitive domains 
on which subjects with a psychotic disorder performed significantly worse than 
healthy controls. The lack of effect of M1 blockade on attention and vigilance in 
chapter 3 suggests that this cognitive domain may be primarily modulated by the 
nAChRs or other mAChR subtypes. This would be in line with previous studies 
(chapter 2) describing a positive effect of nicotine in healthy smoking and non-
smoking individuals (18) and nicotine and nicotinic α7 receptor agonists on 
attention in schizophrenia (19,20). Moreover, non-selective mAChR antagonists 
such as scopolamine have been found to impair attention, besides memory (21). 
To summarize, these findings confirm a role for the muscarinic cholinergic, and 
possibly nicotinergic system in cognitive functioning in subjects with a psychotic 
disorder, warranting further research. To investigate our hypothesis of more 
prominent cholinergic abnormalities in chronic patients, future studies should 
include both psychosis patients in the early phase and in a later stage of the 
disease. Alternatively, a longitudinal design could be used to examine progressive 
cholinergic abnormalities in psychosis. Moreover, future studies using a similar 
paradigm should use multiple day treatment with biperiden to examine delayed 
effects on cognition. Preferably, future research includes a direct in-vivo 
measurement of M1 receptor expression using for example 
123I-IDEX single photon 
emission computed tomography (SPECT) imaging in both patients and healthy 
controls (22).      
 
Neurobiological mechanisms underlying substance use disorders and 
continued, frequent cannabis use 
The second part of this dissertation was aimed at identifying neurobiological 
processes involved in substance use and substance use disorders, focusing on 
mechanisms cannabis use. In chapters 5 and 6 we tested the (predictive) relation 
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between working memory network function (as a part of regulatory executive 
functions and cognitive control) and cue-reactivity (as a part of motivational 
processes) and continued, frequent cannabis use over a 3-year period. Both 
processes could provide new insights in the development of substance use 
disorders since they are considered features of two core aspects underlying 
addiction: imbalanced regulatory functions and motivational processes (23–26). In 
chapter 5, we found that working memory task performance was comparable 
between heavy cannabis users and healthy controls and increased in both groups 
after 3 years. However, working memory network function did not differ between 
the two studied groups and did not change over the  3-year period, implying that 
cannabis does not have negative effects on working memory network function. 
This would in turn suggest that the effects on working memory performance and 
function may be substance specific since impaired working memory has been 
found in heroin and cocaine users (27–29). Furthermore, the lack of impaired 
working memory in gambling addicts (27) could indicate that impaired working 
memory is the result of the use of specific substances of abuse instead of it playing 
a causal role in the overall development of substance use disorders. These 
hypotheses could be investigated in future longitudinal studies. By means of 
regular monitoring of working memory network function in a large cohort of non-
using, recreational using and heavy substance using adolescents, more insight can 
be provided in the causal role of working memory network functioning in 
development of substance use disorders. By comparing groups of different 
substance users, substance specific negative effects on working memory can be 
examined.  
Interestingly, although in the baseline study working memory network functioning 
was found to predict cannabis use after 6 months, such a predictive relation was 
not found after 3 years. These contradictory findings could be due to loss of power 
since 7 heavy cannabis users dropped out at follow-up. Therefore, replication in a 
bigger sample is warranted. However, these findings could also indicate that 
predictors of short-term cannabis use differ from those predicting long-term use. 
Alternatively, given the predictive relation between cannabis cue-induced activity 
in the dorsal striatum and problem severity we found in chapter 6, this could 
indicate that regulatory executive control processes and motivational processes 
have differential roles in recreational cannabis use and problematic use, since 
motivational processes are considered to be expressions of sensitized and 
conditioned responses towards substance related cues (26). Since neural cue-
reactivity did not predict the amount of cannabis use at follow-up, this suggests 
that cannabis-induced activity in the dorsal striatum could be a predictor of 
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cannabis addiction. Unfortunately, cannabis dependence was not assessed at 
baseline, causing this hypothesis to remain speculative. Contrary to the differential 
effects of different substances on working memory, striatal cue-reactivity is less 
likely to be substance specific since comparable results have been found in heavy 
alcohol users and addiction (30–32). Motivational processes are mediated by the 
reinforcing properties of substances because of the ability to strengthen the 
conditioned response (33). During transition from recreational (reward driven drug 
use) to addiction, a shift occurs from positive reinforcing effects of substances and 
impulsive behavior, mediated by the ventral striatum and the medial prefrontal 
cortex, to automatic, compulsive drug use and negative reinforcement 
(withdrawal) which has been linked to the dorsal striatum and lateral prefrontal 
cortex (25,34).  
The results described in chapter 7 suggest that genetic factors may contribute to 
the rewarding properties of substance of abuse and thus mediate motivational 
processes including cue-reactivity. In this chapter we found a low prevalence and 
decreased risk of substance use and substance use disorders in patients with 
22q11.2 deletion syndrome (22q11DS), a genetic disorder characterized by a 
deletion on chromosome 22. We hypothesized that this lower risk of substance 
use and substance use disorders may be related to different reward processing in 
these patients. fMRI studies have found a decreased striatal BOLD response in 
subjects with substance use disorders during non-drug related reward anticipation 
(35,36) and increased brain activation during drug reward anticipation (37). 
Although little research has been conducted on reward processing in 22q11DS, 
one study reports no difference in striatal activity during monetary reward 
anticipation and decreased activation in medial frontal areas in these patients (38), 
which could indicate a decreased hedonic response. A decreased hedonic response 
could in turn be related to the decreased risk of substance use in these patients. 
These potential reduced rewarding effects of substances in 22q11DS could be 
related to dopaminergic abnormalities as a result of reduced COMT activity in 
these patients (39). Processing of reward is primarily modulated by dopaminergic 
neurons projecting from the  ventral tegmental area (VTA) to the nucleus 
accumbens, which is part of the ventral striatum, and frontal cortex (40). The 
dopaminergic system as well as the striatum and frontal cortex are strongly 
involved in both psychotic and substance use disorders. Interestingly, despite the 
high risk of developing a psychotic disorder in 22q11DS, we did not find a relation 
between psychosis and substance use in these patients despite increased 
substance use and substance use disorders in schizophrenia. Studying the relation 
between altered neurobiological mechanisms due to 22q11DS and patterns of 
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substance use could provide more insight in the role of specific genes in the 
development of substance use disorders in both psychotic and healthy 
populations. Future genetic studies should therefore focus on genes lying within 
the deleted region of 22q11DS. Furthermore, studying the role of dopaminergic 
abnormalities (related to genetic variation) in reward processing in 22q11DS, 
psychosis and substance use disorders using a similar paradigm could provide 
further insight in the role of motivational processes underlying substance use 
disorders. 
 To summarize, regulatory executive functions and motivational processes may 
have differential roles in the transition from recreational substance use to 
substance use disorders.  
Methodological considerations  
The results described and discussed in this dissertation should be considered in the 
context of several methodological strengths, limitations and differences between 
studies. Although strengths and limitations are described in the separate chapters, 
a few overall strengths and limitations as well as differences in methods are 
mentioned here because they are important for the entire research field.   
Contrary to the majority of previous conducted studies, an important strength of 
the studies described in chapters 3 and 4 are the inclusion of medication-free 
subjects with a psychotic disorder as this eliminates acute confounding effects of 
antipsychotics. Furthermore, we conducted an extensive and well validated 
cognitive test battery (CANTAB) which is considered to be the ‘gold standard’ in 
psychosis research, enabling us to differentiate between the separate cognitive 
domains critically impaired in schizophrenia as established by the MATRICS. An 
important strength of the studies described in chapters 5 and 6 is the use of a 
longitudinal design. These studies are the first studies that  used a 3-year follow-up 
measurement enabling examining consequences of long-term use cannabis. 
The unsatisfactory results of the studies that were reviewed in chapter 2 could be 
at least partly related to methodological shortcomings of several of the reviewed 
studies. For example, in pharmacological intervention studies, the agent of interest 
is often prescribed as add-on therapy besides antipsychotic medication which may 
interact with the added agent since the exact mechanism of actions of 
antipsychotics are often not known (41). Moreover, these mechanisms of action 
differ across the different types of antipsychotic drugs, which is often not 
controlled for. An additional problem when studying neurobiological mechanisms 
in psychosis is excessive substance use in a substantial number of patients since 
substances of abuse, including alcohol, nicotine and cannabis influence the results. 
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Moreover, methodological differences between studies make it difficult to 
compare results of these studies. For example, use of different cognitive tests and 
different doses of medication could contribute to the inconsistent findings across 
studies. To minimize these methodological differences, the MATRICS initiative has 
been established, and since then a shift to standardized test batteries is 
observable.    
When comparing our findings described in chapter 4 to other studies, it is 
noticeable that the results vary greatly between studies. These inconsistent 
findings are probably related to differences in data acquisition and analyzing 
methods. Perhaps the most important difference between studies is the strength 
of the magnetic field (expressed in Tesla) used. Since the different resonance 
signals are determined by the strength of the external magnetic field (42), higher 
field strength leads to more specific, reliable results. Higher field strength 
increases the signal to noise ratio (SNR) and narrows the width of the peak 
resulting in better spectral resolution and sensitivity (42). Other important factors 
contributing to the reliability of MRS data are the size and location of the brain 
region measured (42). Because of differences in magnetic susceptibility between 
tissue types, it is difficult to acquire spectra of good quality in brain regions 
adjacent to other types of tissue such as bone, fat and water (43). This also 
emphasizes the importance of correcting for the amount of cerebrospinal fluid 
(CSF) within the voxel of interest which is not always done. Furthermore, 
discrepancies in findings between studies could be related to the methods used for 
analyzing the data. Some studies reported absolute metabolite concentrations 
whereas others reported ratios with creatine. Although creatine is a relative stable 
metabolite and these ratios are considered to have good intra-subject validity, 
between subjects validity of creatine ratios have been questioned because a 
decrease in creatine with increasing age has been reported in patients with 
schizophrenia (44) but not in controls (44,45).   
When interpreting the findings described in the separate chapters, some 
limitations have to be taken in to account. First, with the exception of chapter 7, 
the sample sizes of the conducted studies were modest, which could have led to 
insufficient power and subsequently type II errors. Furthermore, the heavy 
cannabis users (chapters 5 and 6) used other substances (alcohol, nicotine and 
recreational drugs) in addition to cannabis thereby confounding the effects of 
cannabis use. Moreover, despite instructions to refrain from substance use 24 
hours prior to participation, a few subjects with a psychotic disorder (chapters 3 
and 4) tested positive on a urine drug screening. Although analyses were repeated 
without these particular subjects and yielded comparable results, possible 
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confounding effects of substance use cannot be ruled out. Finally, the inclusion 
criteria may have caused a selection bias. In chapters 3 and 4, we included 
medication-free psychotic subjects. Although this has the important benefit of 
eliminating acute confounding effects of antipsychotic drug use, this may have led 
to a selection bias of relatively well functioning psychotic subjects thereby limiting 
generalizability of our findings. In chapters 5 and 6, at baseline heavy cannabis 
users without a history or present diagnosis of substance use disorders were 
included. Since heavy cannabis use was defined at baseline as using cannabis at 
least 10 days per month for at least two years, we may have selected a group of 
well-functioning cannabis users which could partially explain the negative findings 
in chapter 5. 
Clinical implications and future directions 
All studies described in this dissertation have been carried out with the aim of 
increasing knowledge about neurobiological mechanisms underlying cognitive 
symptoms of psychotic disorders and substance use disorders in order to 
contribute to the development of new, effective treatment and prevention 
strategies. Although there is still much unknown and we have a long way to go 
before we have unraveled these complex mechanisms, the studies described in 
this dissertation have provided new insights which could benefit clinical practice 
and give rise to further research.  
First, the studies reviewed in chapter 2 outline that distinct domains of cognition 
are modulated via different neurobiological mechanisms. Therefore, future studies 
investigating neurobiological mechanisms of cognitive impairment in psychosis 
should differentiate between separate cognitive domains. Regarding clinical 
practice, these findings plead for a more individually oriented treatment approach 
given the highly heterogeneous (cognitive) profile of psychotic disorders instead of 
a protocol based approach. Although protocols and treatment guidelines are 
useful, these findings highlight the need for extensive mapping of the individual 
profile and to accordingly adjust the treatment approach. However, development 
of pharmacological agents with a selective mechanism of action has been proven 
difficult given the interaction between different neurobiological systems. 
Nevertheless, several add-on pharmacological agents were found to effectively 
enhance different cognitive domains and their use in clinical treatment warrant 
further investigation. The Research Domain Criteria (RDoC) approach could be 
suitable for this purpose. RDoC refers to a framework for new ways of studying 
mental disorders, including psychosis, which integrates multiple levels of 
information ranging from self-report to genetic and biological markers in order to 
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better understand basic dimensions of functioning underlying both normal and 
abnormal behavior. The studies described in chapters 3 and 4 provide further 
evidence of a role for the cholinergic system in attention, reasoning and problem 
solving and memory, implying that pharmacological interventions targeting this 
system can improve these cognitive domains in psychosis. Future studies should 
further investigate this in a sample of more severely cognitive impaired patients 
diagnosed with schizophrenia to further investigate altered cholinergic markers in 
psychosis. Nevertheless, psychotic patients may benefit from interventions 
targeting the mAChRs and nAChRs. Indeed, previous studies using M1/4 receptor 
agonist xanomeline already showed improvement in memory as well as psychotic 
symptoms in schizophrenia patients (46). However, xanomeline also produced 
several side effects. Contrary, studies using acetylcholinesterase inhibitors, which 
are mainly prescribed for treatment of Alzheimer’s disease, did not yield positive 
results in schizophrenia (47–49). Therefore, the M1 receptor subtype in particular 
could be value target for memory enhancement as is it may produce less side 
effects due to its relative low expression in the peripheral nerve system.  
With regard to substance use disorders, the predictive relation between putamen 
activity and cannabis use related problem severity described in chapter 6 suggest 
that habit formation should be a focus point in the treatment of cannabis use 
disorders. Increased putamen activity in response to cannabis cues seems already 
to be present in early stages of cannabis use and could therefore be of use in 
preventing a transition from recreational use to dependence. However, despite 
the fact that fMRI is a reliable technique to measure group differences, it is not 
suitable for detecting aberrant activation patterns at the individual level. Yet, 
advances in new, quickly developing techniques such as machine learning may be 
able to change this in the future (50). Nevertheless, given the relative small sample 
we used our findings should be replicated in a bigger sample. Moreover, future 
studies should also investigate whether cue-reactivity also predicts a transition to 
cannabis addiction.   
In addition to identifying risk-factors, identification of protective factors could also 
make a valuable contribution to the development of effective treatment and 
prevention strategies for substance use disorders. The observation of a decreased 
risk for substance use and substance use disorders in patients with 22q11DS 
(chapter 7) indicates that 22q11DS may be a valuable model to study both genetic 
factors underlying substance use disorders as well potential protective 
environmental factors. Moreover, because of the increased risk for psychotic 
disorders in this population, studying patterns of substance use and related 
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disorders could also provide insight in the genetic aspect of substance use 
schizophrenia.  
To conclude, the studies described in this dissertation have provided new insights 
in the neurobiological mechanism underlying cognitive functioning in psychotic 
subjects and substance use disorders. Although these findings are just small pieces 
of a large and highly complex puzzle, these pieces are important for completing 
this puzzle in the future. 
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Het overkoepelende doel van dit proefschrift was om meer inzicht te verkrijgen in 
de onderliggende neurobiologische mechanismen van co-morbide cognitieve 
symptomen bij psychose en aanhoudend, frequent middelengebruik. In het eerste 
deel van dit proefschrift werden neurobiologische mechanismen die ten grondslag 
liggen aan cognitieve symptomen bij personen met een psychotische stoornis 
onderzocht (hoofdstuk 2 - hoofdstuk 4), met een focus op de rol van het 
cholinerge systeem. In het tweede deel van dit proefschrift werden onderliggende 
neurobiologische mechanismen van middelengebruik onderzocht met een focus 
op onderliggende mechanismen van frequent cannabisgebruik (hoofdstuk 5 - 
hoofdstuk 7).  
In hoofdstuk 2 werd de effectiviteit van farmacologische interventies onderzocht 
voor afzonderlijke cognitieve domeinen, die over het algemeen aangedaan zijn in 
patiënten met schizofrenie, zoals bepaald door het MATRICS-initiatief. De 
bestudeerde studies vonden bewijs voor een rol van de dopaminerge D1 receptor 
bij  de informatieverwerkingssnelheid en het logisch redeneren alsook het 
probleemoplossend vermogen. Het serotonerge, GABA-erge en glutamaat systeem 
lijken betrokken te zijn bij verschillende aspecten van geheugen. Dit laatste 
systeem lijkt ook betrokken te zijn bij logisch redeneren en probleemoplossend 
vermogen. Ten slotte werd aannemelijk gemaakt dat aandacht en alertheid 
gemoduleerd wordt door nicotinerge-acetylcholine receptoren. Echter resultaten 
van een beperkt aantal studies gaven aan dat geheugenfuncties mogelijk 
verbeterd kunnen worden door middelen die het muscarine systeem beïnvloeden. 
Over het algemeen toonden deze bevindingen aan dat er verschillende 
mechanismen ten grondslag liggen aan afzonderlijke aspecten van cognitie. Als dit 
inderdaad het geval is, impliceert dit dat patiënten met schizofrenie met 
verschillende cognitieve profielen baat zouden kunnen hebben van verschillende 
interventiestrategieën.  
In hoofdstuk 3 werd de rol van de muscarine M1-receptor in cognitieve functies bij 
personen met een psychotische stoornis onderzocht met behulp van de M1-
antagonist biperideen als een farmacologische challenge. Het blokkeren van de M1 
-receptor verminderde significant zowel het visueel als verbaal leren en  geheugen,
hetgeen aangeeft dat deze receptor een rol speelt in deze cognitieve (dys)functies.
Verder werd een interactie-effect gevonden tussen medicatie en groep voor
logisch redeneren en probleemoplossend vermogen; in de psychosegroep
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verbeterde dit domein na toediening van biperideen, terwijl prestatie op dit 
domein in de gezonde controle groep juist verslechterde na biperideen toediening. 
Het effect van M1 -antagonisme op dit domein was dus verschillend voor beide 
groepen. Het effect van biperideen op de andere cognitieve domeinen was echter 
vergelijkbaar in de psychose- en de gezonde controlegroep. Hoewel deze 
resultaten de rol van de M1-receptor in geheugen bevestigt, geeft het gebrek aan 
een verschillend effect van M1-blokkade  tussen de groepen mogelijk aan dat het 
disfunctioneren van de M1-receptor niet aanwezig was in onze steekproef. Het 
sluit echter niet uit dat dit wel aanwezig is in oudere, chronische patiënten met 
schizofrenie.  
 
Hoofdstuk 4 geeft een toelichting op de rol van het cholinerge systeem in 
psychose en geassocieerde cognitieve stoornissen. We onderzochten of choline 
concentraties in de anterior cingulate cortex (ACC) en het striatum verschilde 
tussen personen met een psychotische stoornis en controles, en of blokkade van 
de M1-receptor de choline concentraties in deze gebieden beïnvloedde. Daarnaast 
werd onderzocht of choline concentraties geassocieerd waren met afzonderlijke 
domeinen van cognitie. Aangetoond werd een significante negatieve correlatie 
tussen aandacht en choline in het striatum bij psychotische personen die afwezig 
was bij controles, hetgeen eerdere bevindingen van de rol van het cholinerge 
systeem in cognitieve symptomen van psychose bevestigt. Het ontbreken van een 
significant verschil in choline concentraties tussen beide onderzochte  groepen, 
zowel na biperideen als placebo, en in beide hersengebieden, geeft mogelijk aan 
dat er geen ernstige cholinerge afwijkingen aanwezig waren in deze steekproef van 
psychotische personen, hoewel we niet kunnen uitsluiten dat er cholinerge 
afwijkingen aanwezig zijn bij chronische schizofreniepatiënten.  
 
In hoofdstuk 5 werd de relatie tussen het functioneren van het 
werkgeheugennetwerk en aanhoudend, frequent cannabisgebruik onderzocht in 
een longitudinale drie jaar durende functionele MRI-studie. Bij de aanvangsmeting 
werd bevonden dat, ondanks een vergelijkbaar werkgeheugennetwerkfunctie en 
prestatie op een werkgeheugentaak  (gedragsmatig) in zware cannabisgebruikers 
en gezonde niet-gebruikende controles, een sterker werkgeheugen netwerkreactie 
geassocieerd was met verhoogd wekelijks cannabisgebruik over een periode van 
zes maanden. De follow-up resultaten lieten zien dat, ondanks verbeterde 
prestatie op de werkgeheugentaak in beide groepen, 
werkgeheugennetwerkfunctie niet veranderde over de periode van drie jaar. In 
tegenstelling tot eerdere bevindingen werd er geen significante associatie 
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gevonden tussen het functioneren van het werkgeheugennetwerk tijdens de 
aanvangsmeting en cannabis-, nicotine-, alcohol- of ander recreationeel 
drugsgebruik. Deze resultaten geven aan dat aanhoudend cannabisgebruik het 
functioneren van het werkgeheugennetwerk niet significant beïnvloedt.  
Voortbordurend op eerdere bevindingen van verhoogde activatie in reactie op 
cannabisstimuli in het  ventrale tegmentumgebied (VTA) in zware 
cannabisgebruikers in vergelijking met controles, alsmede een hogere activatie in 
de ACC, orbitofrontale cortex (OFC) en striatum in meer problematische 
cannabisgebruikers, werden in hoofdstuk 6 de resultaten van een follow-up studie 
beschreven waarin werd onderzocht of hersenactiviteit in reactie op cannabis 
gerelateerde stimuli in deze hersengebieden voorspellend was voor veranderingen 
in wekelijks cannabisgebruik en de ernst van aan cannabis gerelateerde 
problemen. Geen van de onderzochte gebieden voorspelde wekelijks 
cannabisgebruik na drie jaar. Echter, verhoogde activatie in het linker (dorsale) 
striatum voorspelde de ernst van aan cannabis gerelateerde problemen na drie 
jaar, wat aangeeft dat cue-reactiviteit mogelijk een bruikbaar hulpmiddel is in het 
voorspellen van de transitie naar problematisch cannabisgebruik en mogelijk ook 
cannabisafhankelijkheid.  
In hoofdstuk 7 werd de prevalentie van middelengebruik en middelen gebonden 
stoornissen in 22q11.2 (22q11DS) deletie syndroom, een populatie met een hoog 
risico op het ontwikkelen van psychotische stoornissen, bepaald. De deletie op 
chromosoom 22q11.2 die deze groep patiënten definieert, bevat genen die zijn 
geassocieerd met zowel psychotische stoornissen als middelen gebonden 
stoornissen. Derhalve kan het onderzoeken van patronen van middelengebruik bij 
deze patiënten mogelijk waardevolle inzichten geven in de genetische aspecten 
van zowel psychose als middelen gebonden stoornissen. Vergeleken met 
psychotische patiënten (88%) en gezonde controles (82%), was de prevalentie van 
algemeen middelengebruik (37%) en middelen gebonden stoornissen (1.2%) laag 
in 22q11DS-patiënten. Bovendien vonden we dat deze patiënten een verlaagd 
risico hebben op zowel algemeen middelengebruik als alcohol- en nicotinegebruik 
afzonderlijk. Interessant is dat recreationeel drugsgebruik niet verschilde tussen de 
drie groepen. Daarnaast werd binnen de groep 22q11DS-patiënten geen relatie 
gevonden tussen de prevalentie van middelengebruik en psychose, COMT-
genotype en intelligentie quotiënt (IQ). Vergelijkbaar met bevindingen in de 
algemene populatie was middelengebruik gebruikelijker bij mannelijke dan 
vrouwelijke 22q11DS-patiënten. Vervolgonderzoek naar zowel neurobiologische 
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als omgevingsfactoren die bijdragen aan dit verlaagde risico op middelengebruik 
en aan middelen gebonden stoornissen in 22q11DS is nodig, aangezien dit nieuwe 
inzichten kan geven in de genetische aspecten van aan middelen gebonden 
stoornissen bij zowel psychotische patiënten als de algemene populatie.  
 
Concluderend hebben de studies van dit proefschrift nieuwe inzichten 
gegenereerd in de neurobiologische mechanismen die ten grondslag liggen aan co-
morbide cognitieve symptomen in psychose en aan middelen gebonden 
stoornissen. Echter, deze studies hebben ook nieuwe vragen opgeroepen en 
vervolgonderzoek is nodig om deze vragen te beantwoorden en de verkregen 
inzichten te vertalen naar de klinische praktijk. 
  
